Citigroup Inc. Boosts Stock Position in Tempus AI, Inc. $TEM

Citigroup Inc. increased its position in shares of Tempus AI, Inc. (NASDAQ:TEM) by 209.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,792 shares of the company’s stock after acquiring an additional 16,779 shares during the period. Citigroup Inc.’s holdings in Tempus AI were worth $2,001,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Cranbrook Wealth Management LLC acquired a new position in Tempus AI in the 3rd quarter valued at about $25,000. GAMMA Investing LLC acquired a new stake in shares of Tempus AI during the third quarter worth about $28,000. Allworth Financial LP boosted its stake in shares of Tempus AI by 5,000.0% in the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. SouthState Corp boosted its stake in shares of Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company’s stock valued at $32,000 after purchasing an additional 489 shares during the period. Finally, Tsfg LLC grew its holdings in shares of Tempus AI by 1,515.2% in the third quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the transaction, the executive vice president directly owned 79,816 shares in the company, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Andrew Polovin sold 10,949 shares of Tempus AI stock in a transaction on Friday, February 20th. The shares were sold at an average price of $60.31, for a total transaction of $660,334.19. Following the completion of the transaction, the executive vice president directly owned 126,918 shares in the company, valued at $7,654,424.58. The trade was a 7.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 590,109 shares of company stock worth $37,056,566 over the last ninety days. 26.27% of the stock is owned by corporate insiders.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $52.26 on Monday. Tempus AI, Inc. has a 12 month low of $36.22 and a 12 month high of $104.32. The firm has a market capitalization of $9.34 billion, a P/E ratio of -37.06 and a beta of 5.29. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The company’s fifty day moving average price is $60.14 and its 200 day moving average price is $72.59.

Analysts Set New Price Targets

Several brokerages recently weighed in on TEM. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Robert W. Baird assumed coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target for the company. BTIG Research cut their price objective on Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Finally, Stifel Nicolaus set a $60.00 price objective on Tempus AI in a research note on Wednesday, February 25th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and an average price target of $78.15.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.